Biosimilar ranibizumab (BS1) – early experience from Japan (BRIJ study) [PDF]
Anti-vascular endothelial growth factor (VEGF) injections are the mainstay of treatment for retinal vascular diseases. However, despite their efficacy, the cost of long term intravitreal injections poses a significant burden on patients and healthcare ...
Rezaei, Kourous A. +126 more
core +3 more sources
Biosimilar Agents for Psoriasis Treatment: The Perspective of Portuguese Patients
Introduction: Biosimilars are highly similar copies of previously approved original biologic medicines. Their introduction on the market may yield cost reduction.
Alexandra Azevedo +3 more
doaj +1 more source
Biosimilar tenecteplase versus alteplase in acute ischemic stroke: A real world study
Background and Purpose: There is an unmet need for a more effective thrombolytic agent in acute ischemic stroke (AIS) management. Various studies and meta-analysis suggest tenecteplase (TNK) as non-inferior over alteplase (rTPA).
Ayush Mohan +11 more
doaj +1 more source
Medicines under additional monitoring in the European Union [PDF]
Objective: The objective of this study was to analyse the characteristics of medicines subject to additional monitoring. We assessed the following aspects: the criteria applied to approve a medicine as being subject to additional monitoring; the ...
Esther Salgueiro +5 more
doaj +1 more source
Launching biosimilar rituximab: an industry opinion on biosimilar uptake in Europe
Richard Trollope and Sue Johnson talk with Henry Ireland, Senior Editor about the recent approval of biosimilar rituximab (Truxima®) & the current state of biosimilar uptake across Europe Richard Trollope, Head of Biosimilars, Mundipharma ...
Henry Ireland +2 more
core +1 more source
Statistical assessment of biosimilar products
[[abstract]]Biological products or medicines are therapeutic agents that are produced using a living system or organism. Access to these life-saving biological products is limited because of their expensive costs. Patents on the early biological products
Chow, SC;Liu, JP +2 more
core +1 more source
Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn's Disease: A Prospective Study [PDF]
No data are available regarding the safety and effectiveness of the biosimilar-to-biosimilar switch of adalimumab in any disease, and in particular in Crohn’s disease (CD).
Vernero, Marta +16 more
core +1 more source
Biosimilar medicines and cost-effectiveness
Steven SimoensResearch Centre for Pharmaceutical Care and Pharmaco-economics, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Leuven, BelgiumAbstract: Given that biosimilars are agents that are similar but not identical to the ...
Steven Simoens
core +1 more source
Biosimilar uptake in the United States: Examining state-level longitudinal trends in biosimilar filgrastim use and their association with biosimilar substitution policies [PDF]
Thesis (Ph.D.)--University of Washington, 2020Defined as medicines manufactured in a living system, biologics have demonstrated high clinical utility for an array of therapeutic areas.
Grewal, Simrun Kaur
core
RESUMEN Objetivo: Determinar los aspectos esenciales de la reglamentación de Costa Rica referente al registro sanitario de biosimilares y compararlos con la información brindada en los dosieres de laboratorios fabricantes de heparina y enoxaparina ...
Rebeca Álvarez Brenes +3 more
doaj +1 more source

